曲妥珠单抗联合帕妥珠单抗对比西妥昔单抗联合伊立替康治疗RAS/BRAF野生型HER2阳性转移性结直肠癌(S1613):一项随机II期试验
本研究为随机II期试验,纳入54例RAS/BRAF野生型HER2阳性转移性结直肠癌患者,按1:1分配至曲妥珠单抗联合帕妥珠单抗组(TP,n=26)或西妥昔单抗联合伊立替康组(CETIRI,n=28)。主要终点无进展生存期(PFS)两组无显著差异,但TP组疗效随HER2基因拷贝数(GCN)升高而显著改善,且≥3级不良事件发生率低于CETIRI组。
要点
- TP组与CETIRI组中位PFS分别为4.7个月和3.7个月,无显著差异。
- HER2 GCN≥20者TP组中位PFS 9.9个月 vs CETIRI组2.9个月,交互作用P=.003。
- TP组≥3级不良事件发生率23.1%,低于CETIRI组的46.1%。
核心结论
- TP似乎是RAS/BRAF野生型HER2阳性转移性结直肠癌患者安全有效的无细胞毒性化疗选择。
- 较高的HER2扩增水平与TP相对于CETIRI更大的临床获益相关。
研究设计与样本
- 随机II期试验,纳入RAS/BRAF野生型、经中心确认HER2阳性(免疫组化3+或2+且原位杂交扩增[H ER2/CEP17比值>2.0])的转移性结直肠癌患者。
- 2017年10月至2022年3月共54例参与者按1:1分配至TP组(n=26)或CETIRI组(n=28)。
- TP方案:曲妥珠单抗6 mg/kg联合帕妥珠单抗420 mg,每3周一次;CETIRI方案:西妥昔单抗500 mg/m2联合伊立替康180 mg/m2,每2周一次;治疗至疾病进展或不可耐受毒性。
- CETIRI组进展后允许交叉至TP。
- 主要终点为无进展生存期(PFS);次要终点包括客观缓解率(ORR)、总生存期、安全性及HER2基因拷贝数(GCN≥20/<20)作为预测因素。
主要发现
- TP组中位PFS为4.7个月(95%CI 1.9至7.6),CETIRI组为3.7个月(95%CI 1.6至6.7),两组无显著差异。
- TP对比CETIRI的疗效随HER2 GCN显著不同:GCN≥20组中位PFS为9.9个月 vs 2.9个月,GCN<20组为3.0个月 vs 4.2个月,交互作用P=.003。
- TP组ORR为34.6%,其中GCN≥20者为57.1%,GCN<20者为9.1%;缓解者中位GCN为29.7,非缓解者为13.2(P=.004)。
- TP组≥3级不良事件发生率为23.1%,CETIRI组为46.1%。
关键数值与推荐
- TP组中位PFS 4.7个月(95%CI 1.9至7.6)vs CETIRI组3.7个月(95%CI 1.6至6.7)。
- HER2 GCN≥20亚组中位PFS:TP组9.9个月 vs CETIRI组2.9个月;GCN<20亚组:TP组3.0个月 vs CETIRI组4.2个月;交互作用P=.003。
- TP组ORR 34.6%(GCN≥20者57.1% vs GCN<20者9.1%);缓解者中位GCN 29.7 vs 非缓解者13.2(P=.004)。
- ≥3级不良事件:TP组23.1% vs CETIRI组46.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: ERBB2 overexpression/amplification in RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC; human epidermal growth factor receptor 2 [HER2]-positive mCRC) appears to be associated with limited benefit from anti-EGFR antibodies and promising responses to dual-HER2 inhibition; however, comparative efficacy has not been investigated. We conducted a randomized phase II trial to evaluate efficacy and safety of dual-HER2 inhibition against standard-of-care anti-EGFR antibody-based therapy as second/third-line treatment in HER2-positive mCRC. METHODS: Patients with RAS/BRAF-WT mCRC after central confirmation of HER2 positivity (immunohistochemistry 3+ or 2+ and in situ hybridization amplified [HER2/CEP17 ratio >2.0]) were assigned (1:1) to either trastuzumab plus pertuzumab (TP; trastuzumab 6 mg/kg and pertuzumab 420 mg once every 3 weeks) or cetuximab plus irinotecan (CETIRI; cetuximab 500 mg/m2 and irinotecan 180 mg/m2 once every 2 weeks) until progression or unacceptable toxicity. Crossover to TP was allowed after progression on CETIRI. The primary end point was progression-free survival (PFS). Secondary end points included objective response rate (ORR), overall survival, safety, and HER2 gene copy number (GCN ≥20/<20) as a predictive factor. RESULTS: Between October 2017 and March 2022, 54 participants were assigned to TP (n = 26) and CETIRI (n = 28). Median PFS did not vary significantly by treatment: 4.7 (95% CI, 1.9 to 7.6) and 3.7 (95% CI, 1.6 to 6.7) months in the TP and CETIRI groups, respectively. Efficacy of TP versus CETIRI differed significantly by HER2 GCN (median PFS, GCN ≥20 [9.9 v 2.9 months] and GCN <20 [3.0 v 4.2 months], respectively; P interaction = .003). On TP, ORR was 34.6% (57.1% with GCN ≥20 v 9.1% with GCN <20) with median GCN of 29.7 versus 13.2 for responders and nonresponders, respectively (P = .004). Grade ≥3 adverse events occurred in 23.1% and 46.1% of participants with TP and CETIRI, respectively. CONCLUSION: TP appears to be a safe and effective cytotoxic chemotherapy-free option for patients with RAS/BRAF-WT, HER2-positive mCRC. Higher levels of HER2 amplification were associated with greater degree of clinical benefit from TP vis-à-vis CETIRI.
引用
- Raghav KPS, Guthrie KA, Tan B, et al. Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial. J Clin Oncol. 2025. PMID: 39761503. doi:10.1200/JCO-24-01710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。